Want to see DE:M12 full AI Analyst Report?
M12 Stock Chart & Stats
€18.36
€0.30(1.71%)
At close: 4:00 PM EDT
€18.36
€0.30(1.71%)
Day’s Range― - ―
52-Week Range€13.62 - €21.70
Previous CloseN/A
Volume52.00
Average Volume (3M)3.50K
Market Cap
€340.89M
Enterprise Value€336.14M
Total Cash (Recent Filing)€60.50M
Total Debt (Recent Filing)€5.90M
Price to Earnings (P/E)17.8
Beta0.33
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.19%
Share Statistics
EPS (TTM)1.09
Shares Outstanding18,555,115
10 Day Avg. Volume1,401
30 Day Avg. Volume3,505
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.94
Price to Sales (P/S)0.97
P/FCF Ratio9.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.03
Revenue Forecast (FY)€137.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage reduces financing pressure and preserves flexibility for clinic expansion, investment, or shareholder returns. Growing equity provides an additional buffer against operating volatility, while modest debt limits the drag from interest costs over the next several quarters.
Strong Recent Cash GenerationStrong operating and free cash flow indicate that reported earnings are translating into usable funds. This supports self-funded growth, improves resilience during demand changes, and gives management more capacity to maintain operations without relying heavily on additional borrowing.
Improved Profitability And Sustained Revenue GrowthMulti-year revenue growth combined with a substantial rise in net income suggests improving scale and operating leverage across the business. A larger earnings base can strengthen reinvestment capacity and provide a more durable foundation for future clinic and product activity.
Bears Say
Revenue Growth Is SlowingThe continued deceleration in annual revenue growth indicates that expansion and demand momentum are moderating. If this pattern persists, slower top-line progression could limit operating leverage, reduce the pace of earnings growth, and make future performance more dependent on margin improvement.
Margin Sustainability Remains UncertainHistorical gross-margin volatility makes it harder to determine whether the stronger profitability achieved through 2024 is durable. Without clear evidence that margins held in 2025, earnings may remain sensitive to treatment mix, pricing, and cost changes over the next several quarters.
Cash Flow Has Been VolatileThe sharp cash-flow trough in 2023 shows that conversion from operations can fluctuate materially between years. Although recent performance is strong, renewed volatility could affect internal funding for expansion, reduce predictability, and complicate capital allocation decisions.
M12 FAQ
What was M1 Kliniken AG’s price range in the past 12 months?
M1 Kliniken AG lowest stock price was €13.62 and its highest was €21.70 in the past 12 months.
What is M1 Kliniken AG’s market cap?
M1 Kliniken AG’s market cap is €340.89M.
When is M1 Kliniken AG’s upcoming earnings report date?
M1 Kliniken AG’s upcoming earnings report date is Nov 18, 2026 which is in 25 days.
How were M1 Kliniken AG’s earnings last quarter?
M1 Kliniken AG released its earnings results on Sep 09, 2026. The company reported €0.52 earnings per share for the quarter.
Is M1 Kliniken AG overvalued?
According to Wall Street analysts M1 Kliniken AG’s price is currently Overvalued.
Does M1 Kliniken AG pay dividends?
M1 Kliniken AG pays a Annually dividend of €1.2 which represents an annual dividend yield of 6.19%. See more information on M1 Kliniken AG dividends here
What is M1 Kliniken AG’s EPS estimate?
M1 Kliniken AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does M1 Kliniken AG have?
M1 Kliniken AG has 18,555,115 shares outstanding.
What happened to M1 Kliniken AG’s price movement after its last earnings report?
M1 Kliniken AG reported an EPS of €0.52 in its last earnings report. Following the earnings report the stock price went up 0.494%.
Which hedge fund is a major shareholder of M1 Kliniken AG?
Currently, no hedge funds are holding shares in DE:M12
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
M1 Kliniken AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.35%
12-Months-Change
Fundamentals
Return on Equity
16.58%
Trailing 12-Months
Asset Growth
-12.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
M1 Kliniken AG
M1 Kliniken AG, a Berlin, Germany-based entity established in 2007 and operating as a subsidiary of MPH Health Care AG, manages medical facilities dedicated to aesthetic and plastic surgery across Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company's operations are segmented into two core divisions: Beauty and Trade. The Beauty segment is responsible for the creation and commercialization of pharmaceutical, medical, and medical technology products tailored for aesthetic medicine and cosmetic dermatology. Meanwhile, the Trade segment engages in the distribution of pharmaceuticals, biosimilars, and other medical products and devices, serving critical therapeutic areas such as oncology, HIV, rheumatology, neurology, cardiovascular conditions, and narcotics. Products are supplied to healthcare professionals, pharmacies, and wholesale distributors under the "M1 Select" brand. M1 Kliniken AG's operational footprint encompasses a network of outpatient specialist centers, a specialized surgical clinic center, and 46 distinct specialist locations branded as "M1 Med Beauty." Additionally, the company is involved in the acquisition, administration, and divestiture of real estate, predominantly within the healthcare industry.
Technical Analysis
Fresenius SE & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―
MATERNUS-Kliniken AG
―
Limes Schlosskliniken AG
―